ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2026

Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study.

Yuanyuan Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.